Sodium Nitroprusside for Blood Pressure Reduction in the ICU (SNP2)

This is a phase 2, multicenter, randomized, double-blind placebo-controlled, parallel group study to determine the persistence of the effect of SNP on blood pressure and to assess the potential for rebound hypertension associated with prolonged infusion in pediatric subjects.

The primary endpoint is the change in MAP during the Blinded Study Drug Administration Phase in the absence of other stimuli.

Inclusion criteria

• Subject is less than 17 years of age.
• An in-dwelling arterial line is clinically indicated.
• Subject's parent or legal guardian is willing and able to give informed parental permission signing and dating an IRB-approved informed parental permission containing all of the elements of informed consent, and subject provides assent, signing an IRB-approved and -required informed assent, if applicable.
• Subject is anticipated to require a minimum of 20 mm Hg (15 mm Hg for subjects < 2 years old) reduction in MAP for at least 12 hours using SNP [i.e., MAPB1 - MAPB2 ≥ 20 mm Hg (15 mm Hg for subjects < 2 years old)]

Exclusion criteria

• Subject weighs < 3.0 kg.
• Subject has a known allergy to SNP.
• Subject has a known mitochondrial cytopathy with a disorder of oxidative phosphorylation or of respiratory chain enzymes.
• Subject has a contraindication to vasodilator therapy for control of blood pressure during surgery or in the intensive care unit.
• Subject has raised intracranial pressure.
• Subject is anticipated to need anti-hypertensive drugs other than Sodium Nitroprusside either IV (e.g. dexmedetomidine, esmolol, etc.) or epidural (e.g.local anesthetics, clonidine, etc.) within three terminal half-lives (3X T½ β) of the blinded study drug period. However, patients receiving stable doses of an anti-hypertensive drug(s) prior to the initiation of study drug may be enrolled.
• Subject has any serious medical condition which, in the opinion of the investigator, is likely to interfere with study procedures.
• Subject is moribund (death likely to occur within 48 hours).
• Subject has a positive result for the urine or serum HCG test administered at screening.
• Subject has participated in other clinical trials for investigational drugs within 30 days prior to enrollment
• Subject has received or will have received Sodium Thiosulfate within 6 hours prior to the start of the open-label period.
• Subject is either on, or anticipated to be on, ECMO.